Compare RGLD & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | UTHR |
|---|---|---|
| Founded | 1981 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 23.9B |
| IPO Year | 1995 | 1999 |
| Metric | RGLD | UTHR |
|---|---|---|
| Price | $232.72 | $541.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $231.14 | ★ $533.21 |
| AVG Volume (30 Days) | ★ 934.6K | 525.9K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ 32.74 | 13.07 |
| EPS | 6.69 | ★ 27.86 |
| Revenue | $1,030,471,000.00 | ★ $1,483,300,000.00 |
| Revenue This Year | $94.45 | $7.05 |
| Revenue Next Year | $3.32 | $13.30 |
| P/E Ratio | $33.79 | ★ $19.13 |
| Revenue Growth | ★ 43.24 | 2.38 |
| 52 Week Low | $150.75 | $266.98 |
| 52 Week High | $306.25 | $548.12 |
| Indicator | RGLD | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 61.14 |
| Support Level | $216.53 | $464.92 |
| Resistance Level | $235.52 | $542.66 |
| Average True Range (ATR) | 9.87 | 13.65 |
| MACD | -5.17 | -0.13 |
| Stochastic Oscillator | 25.10 | 88.72 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.